HIV

Jade Ghosn, Babafemi Taiwo, Soraya Seedat, Brigitte Autran, Christine Katlama*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

84 Scopus citations

Abstract

The benefits of combination antiretroviral therapy (cART) for HIV replication and transmission control have led to its universal recommendation. Many people living with HIV are, however, still undiagnosed or diagnosed late, especially in sub-Saharan Africa, where the HIV disease burden is highest. Further expansion in HIV treatment options, incorporating women-centred approaches, is essential to make individualised care a reality. With a longer life expectancy than before, people living with HIV are at an increased risk of developing non-AIDS comorbidities, such as cardiovascular diseases and cancers. Antiretroviral strategies are evolving towards a decrease in drug burden, and some two-drug combinations have proven efficacy for maintenance therapy. Investigational immune checkpoint inhibitors and broadly neutralising antibodies with effector functions have energised the HIV cure research field as the search for an effective vaccine continues. In this Seminar, we review advances and challenges relating to the goal of an AIDS-free world.

Original languageEnglish (US)
Pages (from-to)685-697
Number of pages13
JournalThe Lancet
Volume392
Issue number10148
DOIs
StatePublished - Aug 25 2018

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'HIV'. Together they form a unique fingerprint.

Cite this